Cost-effectiveness of biennial screening for diabetes related retinopathy in people with type 1 and type 2 diabetes compared to annual screening.
Adult
Aged
Cost-Benefit Analysis
Diabetes Mellitus, Type 1
/ complications
Diabetes Mellitus, Type 2
/ complications
Diabetic Retinopathy
/ diagnosis
Female
Glycated Hemoglobin
Health Expenditures
/ statistics & numerical data
Health Resources
/ economics
Humans
Male
Markov Chains
Mass Screening
/ economics
Middle Aged
Models, Econometric
Quality-Adjusted Life Years
Retrospective Studies
Risk Factors
Social Work
/ economics
Time Factors
Cost-utility analysis
Diabetic retinopathy
Economic impact
Screening
Journal
The European journal of health economics : HEPAC : health economics in prevention and care
ISSN: 1618-7601
Titre abrégé: Eur J Health Econ
Pays: Germany
ID NLM: 101134867
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
12
09
2019
accepted:
21
04
2020
pubmed:
10
5
2020
medline:
16
6
2021
entrez:
10
5
2020
Statut:
ppublish
Résumé
Examine the health and economic impact of extending screening intervals in people with Type 2 diabetes (T2DM) and Type 1 diabetes (T1DM) without diabetes-related retinopathy (DR). Diabetic Eye Screening Wales (DESW). Retrospective observational study with cost-utility analysis (CUA) and Decremental Cost-Effectiveness Ratios (DCER) study. Biennial screening versus usual care (annual screening). Anonymised data from DESW were linked to primary care data for people with two prior screening events with no DR. Transition probabilities for progression to DR were estimated based on a subset of 26,812 and 1232 people with T2DM and T1DM, respectively. DCER above £20,000 per QALY was considered cost-effective. The base case analysis DCER results of £71,243 and £23,446 per QALY for T2DM and T1DM respectively at a 3.5% discount rate and £56,822 and £14,221 respectively when discounted at 1.5%. Diabetes management represented by the mean HbA Extending screening to biennial based on HbA Base case and sensitivity analyses indicate biennial screening to be cost-effective for T2DM irrespective of HbA
Identifiants
pubmed: 32385543
doi: 10.1007/s10198-020-01191-y
pii: 10.1007/s10198-020-01191-y
pmc: PMC7423794
doi:
Substances chimiques
Glycated Hemoglobin A
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
993-1002Subventions
Organisme : National Institute for Social Care and Health Research
ID : RFS-12-02
Références
Thomas, R.L., Halim, S., Gurudas, S., Sivaprasad, S., Owens, D.R.: IDF Diabetes Atlas: a review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018. Diabetes Res. Clin. Pract. 157, 107840 (2019)
pubmed: 31733978
doi: 10.1016/j.diabres.2019.107840
Zhang, P., Gregg, E.: Global economic burden of diabetes and its implications. Lancet Diabetes Endocrinol. 5, 404–405 (2017)
pubmed: 28456417
doi: 10.1016/S2213-8587(17)30100-6
Hex, N., Bartlett, C., Wright, D., Taylor, M., Varley, D.: Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet. Med. 29, 855–862 (2012)
pubmed: 22537247
doi: 10.1111/j.1464-5491.2012.03698.x
American Diabetes Association: Economic costs of diabetes in the US in 2012. Diabetes Care. 36, 1033–1046 (2013)
pmcid: 3609540
doi: 10.2337/dc12-2625
Lloyd, A., Nafees, B., Gavriel, S., Royusculp, M.D., Boye, K.S., Ahmad, A.: Health utility values associated with diabetic retinopathy. Diabet. Med. 25, 618–624 (2008)
pubmed: 18346157
doi: 10.1111/j.1464-5491.2008.02430.x
Pezzullo, L., Streatfeild, J., Simkiss, P., Shickle, D.: The economic impact of sight loss and blindness in the UK adult population. BMC Health Serv. Res. 18, 63 (2018)
pubmed: 29382329
pmcid: 5791217
doi: 10.1186/s12913-018-2836-0
Thomas, R.L., Luzio, S.D., North, R.V., Banerjee, S., Zekite, A., Bunce, C., et al.: Retrospective analysis of newly recorded certifications of visual impairment due to diabetic retinopathy in Wales during 2007-2015. BMJ Open 7, e015024 (2017)
pubmed: 28720613
pmcid: 5541630
doi: 10.1136/bmjopen-2016-015024
American Diabetes Association: Microvascular complications and foot care. Diabetes Care 40(supp 1), S88–S98 (2017)
doi: 10.2337/dc17-S013
Javitt, J.C., Aiello, L.P.: Cost-effectiveness of detecting and treating diabetic retinopathy. Ann. Intern. Med. 124(1 Pt 2), 164–169 (1996)
pubmed: 8554212
doi: 10.7326/0003-4819-124-1_Part_2-199601011-00017
Porta, M., Rizzitiello, A., Tomalino, M., Trento, M., Passera, P., Minonne, A., et al.: Comparison of the cost-effectiveness of three approaches to screening for and treating sight-threatening diabetic retinopathy. Diabetes Metab. 25(1), 44–53 (1999)
pubmed: 10335423
James, M., Turner, D.A., Broadbent, D.M., Vora, J., Harding, S.P.: Cost effectiveness analysis of screening for sight threatening diabetic eye disease. BMJ 320(June), 1627–1631 (2000)
pubmed: 10856062
pmcid: 27406
doi: 10.1136/bmj.320.7250.1627
Javitt, J.C., Aiello, L.P., Chiang, Y., Ferris III, F.L., Canner, J.K., Greenfield, S.: Preventative eye care in people with diabetes is cost-saving to the federal government. Diabetes Care 17(8), 909–917 (1994)
pubmed: 7956643
doi: 10.2337/diacare.17.8.909
Thomas, R.L., Dunstan, F., Luzio, S.D., Roy Chowdhury, S., Hale, S.L., North, R.V., et al.: Incidence of Diabetic Retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: retrospective analysis. BMJ 344, e874 (2012)
pubmed: 22362115
pmcid: 3284424
doi: 10.1136/bmj.e874
Leese, G.P., Stratton, I.M., Land, M., Bachmann, M.O., Jones, C., Scanlon, P., et al.: Progression of diabetes retinal status within community screening programs and potential implications for screening intervals. Diabetes Care 38(3), 488–494 (2015)
pubmed: 25524948
doi: 10.2337/dc14-1778
Olafsdottir, E., Stefansson, E.: Biennial eye screening in diabetic patients without retinopathy 10 year experience. Br. J. Ophthalmol. 91(12), 1599–1601 (2007)
pubmed: 17627978
pmcid: 2095544
doi: 10.1136/bjo.2007.123810
Agardh, E., Tababat-Khani, P.: Adopting 3-year screening intervals for sight-threatening retinal vascular lesions in type 2 diabetic subjects without retinopathy. Diabetes Care 34(6), 1318–1319 (2011)
pubmed: 21562322
pmcid: 3114331
doi: 10.2337/dc10-2308
Looker, H.C., Nyangoma, S.O., Cromie, T., Olson, J.A., Leese, G., Philip, S., et al.: Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish diabetic retinopathy screening programme. Diabetologia 56(8), 1716–1725 (2013)
pubmed: 23689796
pmcid: 3699707
doi: 10.1007/s00125-013-2928-7
UK National Screening Committee. UK NSC diabetic retinopathy recommendation. (2016)
Younis, N., Broadbent, D.M., Vora, J.P., Harding, S.P.: Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye study: a cohort study. Lancet. 361, 195–200 (2003)
pubmed: 12547541
doi: 10.1016/S0140-6736(03)12267-2
Taylor-Phillips, S., Mistry, H., Leslie, R., Todkill, D., Tsertsvadze, A., Connock, M., et al.: Extending the diabetic retinopathy screening interval beyound 1 year: systematic review. Br. J. Ophthalmol. 100, 105–114 (2016)
pubmed: 25586713
doi: 10.1136/bjophthalmol-2014-305938
Leslie, R., Todkill, D., Mistry, H., Taylor-Philips, S., Tsertvadze, A., Clarke, A.: Rapid literature review: would changing diabetic eye screening intervals from the current annual recommendation lead to changed clinical outcomes?. University of Warwick, Warwick (2013)
Chalk, D., Pitt, M., Vaidya, B., Stein, K.: Can the retinal screening interval be safely increased to 2 years for type 2 diabetic patients without retinopathy? Diabetes Care 35(8), 1663–1668 (2012)
pubmed: 22566535
pmcid: 3402259
doi: 10.2337/dc11-2282
Lund, S.H., Aspelund, T., Kirby, P., Russell, G., Einarsson, S., Palsson, O., et al.: Individualised risk assessment for diabetic retinopathy and optimisation of screening intervals: a scientific approach to reducing healthcare costs. Br. J. Ophthalmol. 100, 683–687 (2016)
pubmed: 26377413
doi: 10.1136/bjophthalmol-2015-307341
Livingstone, S.J., Looker, H.C., Hothersall, E.J., Wild, S.H., Linsay, R.S., Chalmers, J., et al.: Risk of cardiovascular disease and total mortality in adults with type 1 diabetes. Scottish registry linkage study. PLoS Med. 9, e1001321 (2012)
pubmed: 23055834
pmcid: 3462745
doi: 10.1371/journal.pmed.1001321
Scanlon, P., Aldington, S.J., Leal, J., Luengo-Fernandez, R., Oke, J., Sivaprasad, S., et al.: Development of a cost-effectivenss model for optimisation of the screening intervals in diabetetic retinopathy screening. Health Technol. Assess. 19, 1–116 (2015)
pubmed: 26384314
pmcid: 4780979
doi: 10.3310/hta19740
The DCCT/EDIC Research Group: Frequency of evidence-based screening for retinopathy in Type 1 diabetes. NEJM. 376, 1507–1516 (2017)
doi: 10.1056/NEJMoa1612836
Thomas, R.L., Dunstan, F.D., Luzio, S.D., Roy Chowdhury, S., Hale, S.L., North, R.V., et al.: Prevalence of diabetic retinopathy within the National screening programme of Wales. UK. BJO. 99, 64–68 (2015)
doi: 10.1136/bjophthalmol-2013-304017
Lyons, R.A., Jones, K.H., John, G., Brooks, C.J., Verplancke, J., Ford, D.V., et al.: The SAIL databank; linking multiple health and social care datasets. BMC Med. Inform. Decis. Making. 9, 3 (2009)
doi: 10.1186/1472-6947-9-3
Lyons, R.A., Hutchings, H., Rodgers, S.E., Hyatt, M.A., Demmler, J., Gabbe, B.J., et al.: Development and use of a privacy-protecting total population record linkage system to support observational, interventional, and policy relevant research. Lancet. 380, s6 (2012)
doi: 10.1016/S0140-6736(13)60362-1
Ford, D.V., Jones, K.H., Verplancke, J., Lyons, R.A., John, G., Brown, G., et al.: The SAIL Databank: building a national architecture for e-health research and evaluation. BMC Health Serv Res 9, 157 (2009)
pubmed: 19732426
pmcid: 2744675
doi: 10.1186/1472-6963-9-157
Harding, S., Greenwood, R., Aldington, S., Gibson, J., Owens, D., Taylor, R., et al.: Grading and disease management in national screening for diabetic retinopathy in England and Wales. Diabet. Med. 20(12), 965–971 (2003)
pubmed: 14632697
doi: 10.1111/j.1464-5491.2003.01077.x
National Institute for Clinical Excellence: Methods for the development of NICE public health guidance. NICE, London (2012)
Royle, P., Mistry, H., Auguste, P., Shyangdan, D., Freeman, K.D., Lois, N., et al. Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evidence. Health Technol. Assess. 19(51), 1–247 (2015)
doi: 10.3310/hta19510
Ibanez-Bruron, M.C., Solebo, A.L., Cumberlund, P.M., Rahi, J.S.: Screening for diabetic retinopathy in children and young people in the UK: potential gaps in ascertainment of those at risk. Diabetic Med (2017)
Diabetic Eye Screening Wales. Annual Report 2015–2016. Public Health Wales (2016)
Eleuteri, A., Fisher, A.C., Broadbent, D.M., Garcia-Finana, M., Cheyne, C.P., Wang, A.H., et al.: Individualised variable-interval risk-based screening for sight-threatening diabetic retinopathy: the Liverpool Risk Calculation Engine. Diabetologia 60, 2174–2182 (2017)
pubmed: 28840258
pmcid: 6448900
doi: 10.1007/s00125-017-4386-0
Diabetes UK. Diabetes in Wales. http://www.diabetes.org.uk/In_Your_Area/Wales/Diabetes-in-Wales/
Walker, R.J., Strom Williams, J., Egede, L.E.: Influence of race, ethnicity, and social determinants of health on diabetes outcomes. Am. J. Med. Sci. 351, 366–373 (2016)
pubmed: 27079342
pmcid: 4834895
doi: 10.1016/j.amjms.2016.01.008